A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

CompletedOBSERVATIONAL
Enrollment

325

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

February 15, 2018

Study Completion Date

March 8, 2018

Conditions
Gram-Positive Bacterial Infections
Interventions
DRUG

Oritavancin

This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.

Trial Locations (21)

11215

New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn

14215

Erie County Medical Center, Buffalo

15212

Allegheny General Hospital, Pittsburgh

15213

University of Pittsburgh Medical Center, Pittsburgh

15801

TruCare Internal Medicine and Infectious Diseases, DuBois

30060

WellStar Health System - Kennestone, Marietta

33912

Florida Infectious Disease Care, Fort Myers

34471

Infectious Diseases Associates of North Central Florida, LLC, Ocala

35243

Birmingham Infectious Disease and Infusion, Birmingham

46260

St. Vincent Hospital and Health Care Center, Inc., Indianapolis

51503

Methodist Jennie Edmundson Hospital, Council Bluffs

58701

Trinity Health Medical Group, Minot

67214

IDC Clinical Research, LLC, Wichita

73109

Infectious Diseases Consultants of OKC, Oklahoma City

77380

Houston Center For Infectious Diseases, The Woodlands

77901

Infectious Disease and Pulmonary, Victoria

79902

Center for Infectious Diseases & Travel Medicine, El Paso

83404

Snake River Research, PLLC, Idaho Falls

84770

Foot & Ankle Institute, St. George

89128

Clinical Infectious Disease Specialists, Las Vegas

93105

Santa Barbara Cottage Hospital, Santa Barbara

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, Inc.

INDUSTRY